Press Releases

Novartis Strengthens Cardiovascular Portfolio with $3.08 Billion Anthos Therapeutics Acquisition

Mar 24, 2025, 08:22 AM by
Anthos Therapeutics, Inc., a business that produces abelacimab (full human monoclonal antibody), a late-stage medication being developed to prevent stroke and systemic embolism in patients with atrial fibrillation, has agreed to be acquired by Novartis. Upon concluding the deal, Novartis will pay $925 million upfront, subject to certain usual adjustments. If certain sales and regulatory milestones are met, Novartis may also pay an additional $2.15 billion.

In a strategic move to strengthen its cardiovascular portfolio, Novartis has announced its agreement to acquire Anthos Therapeutics, Inc., a biopharmaceutical company specializing in next-generation anticoagulant therapies. The deal, valued at up to $3.08 billion, includes an upfront payment of $925 million, with an additional $2.15 billion contingent upon regulatory and sales milestones.

Strategic Pointers:

  • Acquisition Details: Novartis will pay $925 million upfront, with potential milestone-based payments of up to $2.15 billion.
  • Target Drug: Abelacimab, a fully human monoclonal antibody developed by Anthos Therapeutics, aims to prevent stroke and systemic embolism in atrial fibrillation patients.
  • Strategic Impact: This acquisition reinforces Novartis' commitment to cardiovascular therapies and precision medicine.
  • Regulatory Process: The deal is subject to customary regulatory approvals before finalization.

Anthos Therapeutics has been at the forefront of developing abelacimab, a late-stage investigational therapy with promising potential in reducing thrombotic events while minimizing the risk of bleeding, a common concern with traditional anticoagulants.

The acquisition comes at a time when the monoclonal antibodies therapeutics market is experiencing exponential growth. Monoclonal antibodies are increasingly being adopted across various therapeutic areas, fueling demand and innovation in the sector.

By acquiring Anthos, Novartis aims to bolster its cardiovascular pipeline and reinforce its commitment to addressing unmet needs in stroke prevention and anticoagulation therapy. The deal underscores Novartis’ strategy to invest in innovative treatments that can redefine patient care and expand its presence in the rapidly growing cardiovascular market.

The acquisition is expected to be finalized following customary regulatory approvals. If abelacimab successfully meets its clinical and regulatory milestones, the additional performance-based payments could bring the total deal value to over $3 billion.

Industry analysts view this acquisition as a significant step for Novartis, aligning with its broader objective of advancing precision medicine and enhancing its cardiovascular therapeutic offerings. The move also highlights the growing interest among pharmaceutical giants in developing next-generation anticoagulants that offer improved safety and efficacy profiles.

As the healthcare landscape continues to evolve, the Novartis-Anthos deal could pave the way for a transformative breakthrough in stroke prevention and systemic embolism treatment, potentially benefiting millions of patients worldwide. With the monoclonal antibodies industry set for remarkable growth, Novartis is strategically positioning itself at the forefront of a revolution in biologic-based therapies.

About Novartis:

Novartis is a global healthcare company committed to reimagining medicine to improve and extend people’s lives. With a strong focus on innovation and research, Novartis develops breakthrough treatments in areas such as oncology, immunology, and cardiovascular diseases. The company continues to invest in cutting-edge therapies, positioning itself as a leader in the biopharmaceutical industry.

Web: https://www.novartis.com/

Content Resource: https://www.novartis.com/news/media-releases/novartis-bolsters-late-stage-cardiovascular-pipeline-agreement-acquire-anthos-therapeutics-usd-925-million-upfront

About Anthos Therapeutics:

Anthos Therapeutics is a biopharmaceutical company dedicated to advancing novel treatments in thrombosis and anticoagulation. Backed by leading scientific expertise, Anthos is focused on developing safer and more effective therapies for patients at risk of thrombotic conditions, with abelacimab as its lead candidate in clinical development.

Web: https://anthostherapeutics.com/

Content Resource: https://anthostherapeutics.com/press-release/anthos_2025-02-11_release/

Resource: https://www.towardshealthcare.com/insights/monoclonal-antibodies-therapeutics-market-sizing

Author (Towards Healthcare):

Shivani Zoting: https://www.towardshealthcare.com/author/104